Eli Lilly (LLY) exhibits exceptional growth, profitability, and momentum, reaching a new all-time high today. Shares are up more than 60% over the past year. LLY maintains a 100% “Buy” technical opinion from Barchart. I recommend maintaining a rational stop loss given the stock’s momentum and volatility, despite continued analyst...

Eli Lilly just posted 47.7% revenue growth and its weight-loss drugs are reshaping global healthcare, but whether that momentum turns a four-year investment into a windfall or a disappointment depends on factors most investors overlook.

2026 revenue guidance is USD 85.00-87.00 billion. Eli Lilly stock costs EUR 1,156.50 on October 20,

METiS TechBio enters a collaboration with Eli Lilly to develop next-generation, tissue-specific lipid nanoparticle delivery technologies using METiS’s AI-driven lipid discovery platform.

METiS TechBio’s AiLNP platform uses machine learning models to develop lipid nanoparticles with potentially better tissue specificity that could enhance a drug’s therapeutic performance.

Bristol-Myers Squibb Company (NYSE:BMY) and Eli Lilly and Company (NYSE:LLY) are almost opposites in the pharmaceutical market. One is trying to replace revenue from aging blockbusters, while the other is struggling to keep pace with demand for its newest ones. Yahoo Finance’s most recently available valuation statistics show that Bristol Myers trades at 9.36 times […]

Pennsylvania filed a lawsuit against Eli Lilly (NYSE:LLY) and other defendants on Oct. 20, 2026, alleging coordinated insulin price inflation. The complaint claims drugmakers and pharmacy benefit managers used list price increases and rebate structures to inflate insulin costs for patients. New late breaking clinical trial data for Eli Lilly's Omvoh reported strong efficacy and safety in pediatric ulcerative colitis patients. The insulin pricing lawsuit and Omvoh pediatric results both...

Hong Kong-listed AI drug delivery developer METiS Therapeutics (07666.HK) has struck a strategic collaboration with Eli Lilly (LLY) to jointly develop…

The September 30, 2026 stake uses 941,357,065 shares outstanding on August 3, 2026. None were deemed owned through rights to acquire shares.

Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.

Eli Lilly just crushed earnings again and sits within striking distance of its all-time high, but a looming price war with Novo Nordisk and a dangerously concentrated revenue base raise real questions about how long the momentum holds.

Eli Lilly just crushed earnings again and sits within striking distance of its all-time high, but a looming price war with Novo Nordisk and a dangerously concentrated revenue base raise real questions about how long the momentum holds.

Is this company the biggest dark horse in the chronic weight management space?

Is this company the biggest dark horse in the chronic weight management space?